## Survivorship – Peripheral T-Cell Lymphoma MDAnderson

Making Cancer History®

THE UNIVERSITY OF TEXAS

<del>Cancer</del> Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



Department of Clinical Effectiveness V6 Approved by the Executive Committee of the Medical Staff on 11/19/2024

# Survivorship – Peripheral T-Cell Lymphoma

Making Cancer History®

THE UNIVERSITY OF TEXAS

MDAnderson Cancer Center

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



<sup>1</sup>See Physical Activity, Nutrition, Obesity Screening and Management, and Tobacco Cessation Treatment algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice <sup>2</sup>Includes breast, cervical, colorectal, liver, lung, pancreatic, prostate and skin cancer screening <sup>3</sup>Based on American Society of Clinical Oncology (ASCO) guidelines

#### Survivorship – Peripheral T-Cell Lymphoma MD Anderson <del>Cancer</del> Center

Making Cancer History®

THE UNIVERSITY OF TEXAS

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

## SUGGESTED READINGS

- Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., ... Lenihan, D. (2017). Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Oncology Practice, 35(8), 893-911. doi:10.1200/JCO.2016.70.5400
- Kamboj, M., Bohlke, K., Baptiste, D. M., Dunleavy, K., Fueger, A., Jones, L., ... Kohn, E. C. (2024). Vaccination of adults with cancer: ASCO guideline. Journal of Clinical Oncology, 42(14), 1699-1721. doi:10.1200/JCO.24.00032

Leukemia & Lymphoma Society. (n.d.). Follow-up care and survivorship. Retrieved from https://www.lls.org/treatment/follow-care-and-survivorship

MD Anderson Institutional Policy #CLN1202 - Advance Care Planning Policy Advance Care Planning (ACP) Conversation Workflow (ATT1925)

National Comprehensive Cancer Network. (2024). Survivorship (NCCN Guideline Version 1.2024). Retrieved from https://www.nccn.org/professionals/physician\_gls/pdf/survivorship.pdf

National Comprehensive Cancer Network. (2024). T-cell Lymphomas (NCCN Guideline Version 4.2024). Retrieved from https://www.nccn.org/professionals/physician\_gls/pdf/t-cell.pdf

Nishimura, R. A., Otto, C. M., Bonow, R. O., Carabello, B. A., Erwin, J. P., Fleisher, L. A., ... Thompson, A. (2017). 2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology, 70(2), 252-289. doi:10.1016/j.jacc.2017.03.011

### Survivorship – Peripheral T-Cell Lymphoma MD Anderson

Page 4 of 4

Making Cancer History®

THE UNIVERSITY OF TEXAS

<del>ancer</del> (enter

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

#### **DEVELOPMENT CREDITS**

This cancer survivorship consensus algorithm is based on majority expert opinion of the Survivorship Lymphoma Faculty at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

#### **Core Development Team Leads**

Swaminathan P. Iver, MD (Lymphoma/Myeloma) Ranjit Nair, MD (Lymphoma/Myeloma)

#### **Workgroup Members**

Bouthaina Shbib Dabaja, MD (Radiation Oncology) Julia Dai, MD (Dermatology) Penny Fang, MD (Radiation Oncology) Luis E. Fayad, MD (Lymphoma/Myeloma) Olga N. Fleckenstein, BS<sup>+</sup> Katherine Gilmore, MPH (Cancer Survivorship) Jillian R. Gunther, MD, PhD (Radiation Oncology) Chitra Hosing, MD (Stem Cell Transplantation) Auris Huen, MD (Dermatology) Thoa Kazantsev, MSN, RN, OCN

Luis Malpica Castillo, MD (Lymphoma/Myeloma) Eguono Maples, BSN, RN (Lymphoma/Myeloma) Ellen Mullen, APN (Lymphoma/Myeloma Survivorship) Chelsea Camille Pinnix, MD (Radiation Oncology) Jeremy Leon Ramdial, MD (Stem Cell Transplantation) Alma Maria Rodriguez, MD (Lymphoma/Myeloma) Johnny L. Rollins, MSN, APRN, ANP-C (Cancer Survivorship) Samer A. Srour, MD (Stem Cell Transplantation) Susan Y. Wu, MD (Radiation Oncology Department)

Clinical Effectiveness Development Team